Published in Pharma Law Weekly, September 6th, 2005
In particular, one of the compounds in the portfolio, FB642, has shown promise in early clinical trials as an anticancer drug. Under the license agreement, AmpliMed will take over development of FB642 from UTR and is responsible for maintenance of the FB642 intellectual property portfolio. In return, UTR will receive equity in AmpliMed along with cash payments on...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.